Skip to content
Colorectal Cancer Clinical Trials

Los Angeles, California

Colorectal cancer clinical trials in Los Angeles, CA

92 colorectal cancer studies are recruiting participants at sites in Los Angeles as of November 16, 2026, according to ClinicalTrials.gov. Colorectal Cancer Clinical Trials can help you understand your options and connect with a study team.

Call (888) 385-9581
  • No cost to ask
  • Taking part is voluntary
  • Studies are independently reviewed

Los Angeles at a glance

  • 92 studies are recruiting at a site in Los Angeles.
  • By phase: Phase 1 (30), Phase 1/2 (28), Phase 2 (12), Phase 2/3 (2), Phase 3 (8), Phase 4 (1), No phase (8), Observational (3). Studies of devices and behavioral approaches have no phase.
  • By sponsor: industry (72), university, hospital or other (19), government (1).
  • Most recent update to one of these records: November 16, 2026.

Studies recruiting in Los Angeles

Basic details from each study's public record (the 30 most recently updated of 92). Select a study to read the full record on ClinicalTrials.gov, including how to contact its team.

  1. Beamion BCGC-1: A Study to Find a Suitable Dose of Zongertinib Used Alone and in Combination With Other Treatments to Test Whether it Helps People With Different Types of HER2+ Cancer That Has Spread

    • Phase 1/2
    • Ages 18 and older
    • All sexes
    Sponsor
    Boehringer Ingelheim
    Study sites
    Ellison Medical Institute · University of California Los Angeles · Valkyrie Clinical Trials
    Registry record
    NCT06324357 · updated
  2. Study of Petosemtamab Plus Chemotherapy Versus Cetuximab or Bevacizumab Plus Chemotherapy in RAS and BRAF Wild Type, Recurrent, Unresectable or Metastatic Colorectal Cancer (LiGeR-CRC2)

    • Phase 3
    • Ages 18 and older
    • All sexes
    Sponsor
    Genmab
    Study site
    Valkyrie Clinical Trials - Los Angeles
    Registry record
    NCT07775287 · updated
  3. A Study of ASP546C in Adults With Gastroesophageal Cancer, Pancreatic Cancer or Other Solid Tumors

    • Phase 1/2
    • Ages 18 and older
    • All sexes
    Sponsor
    Astellas Pharma Global Development, Inc.
    Study site
    START Los Angeles
    Registry record
    NCT07488676 · updated
  4. Virtual Reality for GI Cancer Pain to Improve Patient Reported Outcomes

    • No phase
    • Ages 18 to 99
    • All sexes
    Sponsor
    Cedars-Sinai Medical Center
    Study site
    Cedars-Sinai Medical Center
    Registry record
    NCT04907643 · updated
  5. A Study to Evaluate the Safety, Pharmacokinetics, and Anti-Tumor Activity of VVD-133214 as Monotherapy and in Combination in Participants With Advanced Solid Tumors

    • Phase 1
    • Ages 18 and older
    • All sexes
    Sponsor
    Vividion Therapeutics, Inc.
    Study site
    START Los Angeles
    Registry record
    NCT06004245 · updated
  6. A Clinical Study of Calderasib (MK-1084) With Targeted Therapy and Chemotherapy in People With Colorectal Cancer (MK-1084-012/KANDLELIT-012)

    • Phase 3
    • Ages 18 and older
    • All sexes
    Sponsor
    Merck Sharp & Dohme LLC
    Study site
    Los Angeles Hematology Oncology Medical Group ( Site 0084)
    Registry record
    NCT06997497 · updated
  7. A Phase 1 Dose Escalation and Dose Expansion Trial of KST-6051 in Participants With Advanced Solid Tumors With Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Mutation

    • Phase 1
    • Ages 18 and older
    • All sexes
    Sponsor
    Kestrel Therapeutics, Inc.
    Study site
    Cedars-Sinai Medical Center
    Registry record
    NCT07458347 · updated
  8. A Phase 2 Study of VS-7375 in Patients With KRAS G12D-Mutated Colorectal Cancer

    • Phase 2
    • Ages 18 and older
    • All sexes
    Sponsor
    Verastem, Inc.
    Study sites
    Cedars-Sinai Medical Center · START Los Angeles · Valkyrie Clinical Trials (contact for more locations)
    Registry record
    NCT07659795 · updated
  9. Neoadjuvant Pembrolizumab and Porustobart in Resectable pMMR/MSS Colon Cancer

    • Phase 2
    • Ages 18 and older
    • All sexes
    Sponsor
    Solstice Oncology, Inc.
    Registry record
    NCT07808151 · updated
  10. Study to Test the Safety and Tolerability of PF-07220060 in Participants With Advance Solid Tumors

    • Phase 2
    • Ages 18 and older
    • All sexes
    Sponsor
    Pfizer
    Study site
    Ellison Institute
    Registry record
    NCT04557449 · updated
  11. A Phase 1/2 Study of VS-7375 in Patients With KRAS G12D-Mutated Solid Tumors

    • Phase 1/2
    • Ages 18 and older
    • All sexes
    Sponsor
    Verastem, Inc.
    Study site
    Cedars-Sinai Medical Center
    Registry record
    NCT07020221 · updated
  12. Testing the Addition of Anti-cancer Drug, ZEN003694, to the Usual Chemotherapy Treatment, Cetuximab Plus Encorafenib, for Colorectal Cancer

    • Phase 1
    • Ages 18 and older
    • All sexes
    Sponsor
    National Cancer Institute (NCI)
    Study site
    USC / Norris Comprehensive Cancer Center
    Registry record
    NCT06102902 · updated
  13. A Study Evaluating the Safety and Efficacy of Targeted Therapies in Subpopulations of Patients With Metastatic Colorectal Cancer (INTRINSIC)

    • Phase 1
    • Ages 18 and older
    • All sexes
    Sponsor
    Hoffmann-La Roche
    Study site
    Cedars-Sinai Medical Center
    Registry record
    NCT04929223 · updated
  14. Short Course Radiation Therapy and Combination Chemotherapy for the Treatment of Stage II-III Rectal Cancer

    • Phase 1
    • Ages 18 and older
    • All sexes
    Sponsor
    Jonsson Comprehensive Cancer Center
    Study site
    UCLA / Jonsson Comprehensive Cancer Center
    Registry record
    NCT04703101 · updated
  15. Phase III Study of Ivonescimab or Bevacizumab Combined With FOLFOX in Patients With Metastatic Colorectal Cancer

    • Phase 3
    • Ages 18 and older
    • All sexes
    Sponsor
    Summit Therapeutics
    Registry record
    NCT07228832 · updated
  16. FOLFIRI and Bevacizumab With or Without Pelareorep for Second-Line Treatment of Metastatic RAS-Mutated, Microsatellite-Stable Colorectal Cancer

    • Phase 2
    • Ages 18 and older
    • All sexes
    Sponsor
    Oncolytics Biotech
    Study sites
    Clinical Research Advisors (Downtown LA) · Clinical Research Advisors (West Hollywood)
    Registry record
    NCT07446322 · updated
  17. Five or Ten Year Colonoscopy for 1-2 Non-Advanced Adenomatous Polyps

    • No phase
    • Ages 45 to 70
    • All sexes
    Sponsor
    NRG Oncology
    Study sites
    Kaiser Permanente Los Angeles Medical Center · Kaiser Permanente West Los Angeles · UCLA / Jonsson Comprehensive Cancer Center
    Registry record
    NCT05080673 · updated
  18. Colon Adjuvant Chemotherapy Based on Evaluation of Residual Disease

    • Phase 2/3
    • Ages 18 and older
    • All sexes
    Sponsor
    NRG Oncology
    Study sites
    Cedars-Sinai Medical Center · Kaiser Permanente Los Angeles Medical Center · Kaiser Permanente West Los Angeles
    Registry record
    NCT05174169 · updated
  19. Study of RAS(ON) Inhibitors in Combination With Ivonescimab in Patients With Solid Tumors

    • Phase 1/2
    • Ages 18 and older
    • All sexes
    Sponsor
    Revolution Medicines, Inc.
    Study site
    USC Norris Comprehensive Cancer Center
    Registry record
    NCT07397338 · updated
  20. A Study of Amivantamab Monotherapy and in Addition to Standard-of-Care Chemotherapy in Participants With Advanced or Metastatic Colorectal Cancer

    • Phase 1/2
    • Ages 18 and older
    • All sexes
    Sponsor
    Janssen Research & Development, LLC
    Study site
    University of California, Los Angeles UCLA
    Registry record
    NCT05379595 · updated
  21. Testing the Addition of Total Ablative Therapy to Usual Systemic Therapy Treatment for Limited Metastatic Colorectal Cancer, ERASur Trial

    • Phase 2
    • Ages 18 and older
    • All sexes
    Sponsor
    Alliance for Clinical Trials in Oncology
    Study site
    Cedars-Sinai Medical Center
    Registry record
    NCT05673148 · updated
  22. A Study of Amivantamab and mFOLFOX6 or FOLFIRI Versus Cetuximab and mFOLFOX6 or FOLFIRI as First-line Treatment in Participants With KRAS/NRAS and BRAF Wild-type Unresectable or Metastatic Left-sided Colorectal Cancer

    • Phase 3
    • Ages 18 and older
    • All sexes
    Sponsor
    Janssen Research & Development, LLC
    Study site
    USC Norris Comprehensive Cancer Center
    Registry record
    NCT06662786 · updated
  23. A Study of Amivantamab and FOLFIRI Versus Cetuximab/Bevacizumab and FOLFIRI in Participants With KRAS/NRAS and BRAF Wild-type Colorectal Cancer Who Have Previously Received Chemotherapy

    • Phase 3
    • Ages 18 and older
    • All sexes
    Sponsor
    Janssen Research & Development, LLC
    Study site
    USC Norris Comprehensive Cancer Center
    Registry record
    NCT06750094 · updated
  24. A Study to Investigate the Safety and Efficacy of KQB368 as Monotherapy in Participants With Advanced Solid Malignancies

    • Phase 1
    • Ages 18 and older
    • All sexes
    Sponsor
    Kumquat Biosciences Inc.
    Study site
    START Los Angeles
    Registry record
    NCT07542704 · updated
  25. A First-in-human Study of RLY-8161 in Advanced NRAS-Mutant Solid Tumors

    • Phase 1/2
    • Ages 18 and older
    • All sexes
    Sponsor
    Relay Therapeutics, Inc.
    Study site
    University of California, Los Angeles
    Registry record
    NCT07584226 · updated
  26. A Phase 1 and 2 Study of VMD-102 in Hepatocellular Carcinoma and Other Solid Tumors

    • Phase 1/2
    • Ages 18 to 75
    • All sexes
    Sponsor
    VM Discovery, Inc.
    Study site
    The Angeles Clinic and Research Institute (#601)
    Registry record
    NCT07636785 · updated
  27. Study of Petosemtamab Plus Chemotherapy Versus Cetuximab Plus Chemotherapy in RAS and BRAF Wild-type, Unresectable or Metastatic, Left-sided Colorectal Cancer (LiGeR-CRC1)

    • Phase 3
    • Ages 18 and older
    • All sexes
    Sponsor
    Genmab
    Study site
    Valkyrie Clinical Trials - Los Angeles
    Registry record
    NCT07702032 · updated
  28. EIK1005-002: A Clinical Research Study Evaluating EIK1005, a Werner Helicase Inhibitor, as Monotherapy and in Combination With Pembrolizumab in Participants With Advanced Solid Tumors Including Microsatellite Instability High (MSI-H) Tumors

    • Phase 1/2
    • Ages 18 and older
    • All sexes
    Sponsor
    Eikon Therapeutics
    Study site
    California Research Institute (CRI)
    Registry record
    NCT07262619 · updated
  29. A Clinical Study of MK-2870 Alone or With Other Treatments to Treat Gastrointestinal Cancers (MK-9999-02A)

    • Phase 1/2
    • Ages 18 and older
    • All sexes
    Sponsor
    Merck Sharp & Dohme LLC
    Study site
    UCLA ( Site 0317)
    Registry record
    NCT06428409 · updated
  30. A Study of MGC026 in Participants With Advanced Solid Tumors

    • Phase 1
    • Ages 18 and older
    • All sexes
    Sponsor
    MacroGenics
    Study site
    The Angeles Clinic and Research Institute
    Registry record
    NCT06242470 · updated

Source: ClinicalTrials.gov. Data processed . See every colorectal cancer study recruiting in Los Angeles, CA on ClinicalTrials.gov.

Ask about studies near Los Angeles

Tell us what you are looking for and a coordinator will contact you to talk through your options. Asking does not commit you to anything.

How should we reach you?
Add a message or the best time to reach you (optional)

Please do not include detailed medical information.

Before you contact a study

More locations in California

About these listings

These listings come from ClinicalTrials.gov, the study registry run by the U.S. National Library of Medicine. The data were processed on November 16, 2026. We show part of each public record (its title, phase, sponsor, basic eligibility and sites in this area) exactly as registered, and we group studies by place. Nothing in a record is reworded.

Colorectal Cancer Clinical Trials does not run these studies and is not affiliated with their sponsors. A listing is not a recommendation, and only a study's own team can tell you whether you may be eligible. Follow the link on any study to read its full record and contact that team directly, or ask us and a coordinator will help you understand your options. How we source and check what we publish.

Sources and further reading

Ask about a study

A coordinator will contact you. Asking does not commit you to anything.

Call (888) 385-9581

or send a short form

How should we reach you?

Call